Chris Yin Wei Chan, Mun Keong Kwan, Lim Beng Saw, Hussin Paisal
Abstract
The clinical application of recombinant bone morphogenetic protein in spinal surgery has been shown to be safe and effective. However, its use in minimally invasive spine surgery has been limited to anterior interbody fusion procedures. To date, no study has evaluated the feasibility of percutaneous posterolateral fusion in the spine utilizing rhBMP-2.
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 November 2013.
All research outputs
#18,354,532
of 22,731,677 outputs
Outputs from Clinical Spine Surgery
#623
of 809 outputs
Outputs of similar age
#237,186
of 310,524 outputs
Outputs of similar age from Clinical Spine Surgery
#28
of 62 outputs
Altmetric has tracked 22,731,677 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 809 research outputs from this source. They receive a mean Attention Score of 3.2. This one is in the 4th percentile – i.e., 4% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,524 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 62 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
